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SUMMARY
Transcription factor p63 is a key regulator of
epidermal keratinocyte proliferation and differentia-
tion. Mutations in the p63 DNA-binding domain are
associated with ectrodactyly, ectodermal dysplasia,
and cleft lip/palate (EEC) syndrome. However, the
underlying molecular mechanism of these mutations
remains unclear. Here, we characterized the tran-
scriptome and epigenome of p63 mutant keratino-
cytes derived from EEC patients. The transcriptome
of p63 mutant keratinocytes deviated from the
normal epidermal cell identity. Epigenomic analyses
showed an altered enhancer landscape in p63
mutant keratinocytes contributed by loss of p63-
bound active enhancers and unexpected gain of en-
hancers. The gained enhancers were frequently
bound by deregulated transcription factors such as
RUNX1. Reversing RUNX1 overexpression partially
rescued deregulated gene expression and the
altered enhancer landscape. Our findings identify a
disease mechanism whereby mutant p63 rewires
the enhancer landscape and affects epidermal cell
identity, consolidating the pivotal role of p63 in
controlling the enhancer landscape of epidermal
keratinocytes.
INTRODUCTION
The transcription factor (TF) p63 is an ancient member of the p53
gene family. Different from p53 that has a convincing function in
tumor suppression, p63 is a key regulator of development of the
epidermis, specifically in epidermal stem cell self-renewal,
morphogenesis, and directing differentiation programs (Candi
et al., 2008; Mills et al., 1999; Yang et al., 1999). Several p63 iso-
forms have been reported, and all isoforms contain the DNA-
binding domain (Kouwenhoven et al., 2015b).
The role of p63 in epidermal development has been estab-
lished by two independent p63 knockout mouse models (Mills
et al., 1999; Yang et al., 1999). These p63-deficient mice do
not have the epidermis and epidermal-related appendages. Dur-
ing embryonic development, p63-deficient mice develop a
normal ectoderm with Krt8- and Krt18-positive simple epithelial
cells. However, they fail to initiate embryonic stratification or pro-
duce mature Krt5- and Krt14-positive epithelial and epidermal
cells, termed keratinocytes (Shalom-Feuerstein et al., 2011).
These findings demonstrate that p63 is essential and required
for the commitment to a proper epidermal cell fate during
development.
In keratinocytes, p63 plays important roles in both proliferation
and differentiation. The p63 protein, mainly the DNp63a isoform,
is expressed at a high level in proliferating keratinocytes in the
basal layer of the epidermis. Upon stratification, its expression
level is reduced (Candi et al., 2007). Knockdown of p63 in kera-
tinocytes affects proliferation and prevents cells from differenti-
ation (Truong et al., 2006). At the molecular level, knockdown of
p63 induces genes controlling cell-cycle arrest, such as p21
(CDKN1A) (LeBoeuf et al., 2010), and downregulates genes
that are important for epidermal differentiation, such as PERP
and KRT14 (Ihrie et al., 2005; Romano et al., 2007). These data
show that p63 represses cell-cycle-arrest genes to promote pro-
liferation and activates epidermal differentiation genes to induce
differentiation.
In recent years, a number of epigenomic profiling studies es-
tablished the master regulator role of p63 in the genome of ker-
atinocytes, predominantly in controlling enhancers (Bao et al.,
2015; Kouwenhoven et al., 2015a; Rinaldi et al., 2016). p63 book-
marks genomic loci and cooperates with specific TFs to activate
epidermal genes via active enhancers. Consistently, transpo-
sase accessible chromatin with high-throughput sequencing
(ATAC-seq) analysis showed that p63-binding sites are preferen-
tially located in nucleosome-enriched regions in epidermal kera-
tinocytes, and these sites are inaccessible in cell types where
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p63 is not expressed (Bao et al., 2015). In keratinocytes, p63
cooperates with an ATP-dependent chromatin remodeling fac-
tor, BAF1, to make these regions accessible. It has also been
shown that p63 directly regulates chromatin factors such as
Satb1 and Brg1 that play roles in higher-order chromatin remod-
eling, covalent histone modifications, and nuclear assembly
(Fessing et al., 2011;Mardaryev et al., 2014). These data suggest
that p63 regulates epidermal cell fate determination and differen-
tiation not only through direct target genes but also via modu-
lating the chromatin landscape.
The key role of p63 in epidermal development has also been
demonstrated in human disease models. Heterozygous muta-
tions of TP63 encoding p63 cause a spectrum of developmental
disorders. Among them, ectrodactyly, ectodermal dysplasia,
and cleft lip/palate (EEC) syndrome is caused by point mutations
located in the p63 DNA-binding domain and manifests ecto-
dermal dysplasia with defects in the epidermis and epidermal-
related appendages, limb malformation, and cleft lip and/or
palate (Rinne et al., 2007). Five hotspot mutations affecting
amino acids, R204, R227, R279, R280, and R304, have been
found in90% of the EEC population, and these EEC mutations
were shown to disrupt p63 DNA binding and result in impaired
transactivation activity (Browne et al., 2011; Celli et al., 1999).
Therefore, these mutant p63 proteins have been proposed to
have a dominant-negative effect on wild-type p63, probably by
abolishing DNA binding as a result of tetramerization of wild-
type and mutant proteins (Brunner et al., 2002). Furthermore,
mouse genetic studies support the dominant-negative model.
Heterozygous p63 knockout mice do not show any ectodermal
phenotype (Mills et al., 1999; Yang et al., 1999), whereas hetero-
zygous knockin mice carrying an EECmutation resemble the hu-
man phenotype (Vernersson Lindahl et al., 2013).
Although the role of p63 in normal epidermal development and
differentiation has been demonstrated, the molecular mecha-
nism by which p63 mutations cause the epidermal phenotype
in diseases is not yet understood. We previously reported that
p63 mutant keratinocytes derived from EEC patients could not
fully differentiate toward terminal stratification in both 2D and
3D cellular models (Shen et al., 2013). In this study, EEC patient
keratinocytes carrying three hotspot mutations (R204W, R279H,
and R304W) were assessed by transcriptomic and epigenomic
analyses to identify the underlying molecular mechanism. Our
data showed that deregulated gene expression accompanied
by a rewired enhancer landscape leads to a less defined
epidermal cell identity of p63 mutant keratinocytes, which
potentially contributes to the pathogenic mechanism of EEC
syndrome.
RESULTS
Loss of Characteristic Epidermal Expression Profiles in
p63 Mutant Keratinocytes
Using an established in vitro differentiation model of epidermal
keratinocytes (Kouwenhoven et al., 2015a), we characterized
gene expression differences between keratinocytes derived
from non-EEC individuals (control) and EEC patients carrying
mutations in the DNA-binding domain of p63 (R204W, R279H,
and R304W, p63 mutant) (Figures 1A and 1B). Similar to our pre-
vious report (Shen et al., 2013), p63 mutant keratinocytes re-
tained largely unchanged morphology at the terminal stage of
differentiation compared to the multilayer cell structures of con-
trol keratinocytes on day 7 (Figure S1A), indicating that they were
unable to fully differentiate. To better characterize these mutant
keratinocytes at the molecular level, we performed RNA-
sequencing (RNA-seq) analyses. In principal-component anal-
ysis (PCA), gene expression of control keratinocytes from day
0 to day 7 moved along the principle component 1 (PC1) axis
(51%) that probably defines the differentiation process, whereas
mutant keratinocytes remained at the left side of PC1 (Figure 1C).
Consistently, DAVID Gene Ontology (GO) annotation (Dennis
et al., 2003) of the top 500 genes associated with PC1 showed
terms related to epidermis development and keratinocyte differ-
entiation (Tables S1A and S1B). Many deregulated genes were
validated by qRT-PCR and at the protein level (Figure S1B).
These molecular data confirmed the differentiation defect of
p63 mutant keratinocytes.
We next analyzed differentially expressed (DE) genes (p < 0.05)
between control and p63 mutant keratinocytes during differenti-
ation. Overall, 3,373 genes were upregulated and 4,595 genes
were downregulated in p63 mutant keratinocytes (Table S1D),
which were distinguished into four clusters (Figure 1D; Table
S1E). Among the upregulated genes (EC1), some were generally
not expressed or expressed at a low level in control keratino-
cytes. There was an enrichment of genes involved in extracellular
structureorganization, actin cytoskeletonorganization, andmus-
cle cell function (e.g., ACTG1 andMYH10) (Table S1F). TF genes
in this cluster include SOX4, TEAD2, and RUNX1, which are
widely expressed in many cell types, and a number of Antp ho-
meobox family members, such as HOX genes. Interestingly,
TP63 was also detected in EC1, and DNp63 was the isoform de-
tected in both control and mutant keratinocytes (Figure S1C).
Compared to the decreased p63 expression during differentia-
tion in control keratinocytes, an increased p63 expression at
theproliferation stagewasobserved inp63mutant keratinocytes,
and this expression level stayed at a high level through differenti-
ation (Figure S1C).
The 4,595 downregulated genes whose expression was
dynamically induced during differentiation in control keratino-
cytes remained low and largely unchanged in p63 mutant kerati-
nocytes. These genes were grouped into three clusters (EC2,
EC3, and EC4) (Tables S1G–S1I). Genes in EC2 showed a sharp
increase in gene expression on day 7 in control keratinocytes.
Many of these genes were involved in catabolic pathways and
cell death (e.g.,UBE4A andCDKN2D). Genes in EC3 were highly
expressed at the proliferation stage on day 0, and expression
went down during differentiation. They were mainly involved in
cell-cycle regulation (e.g., CDC20 and KIFC1). Finally, genes in
EC4 showed a progressive upregulation in control keratinocytes,
and many of them were involved in ectoderm development and
keratinocyte differentiation. The TF genes in this cluster included
OVOL1 and KLF4, and known p63 co-regulators, such as
TFAP2A andNFE2L2. Of note, consistent with themorphological
changes (Figure S1A), the deregulated gene expression was
more evident in mutant keratinocytes carrying R204W and
R304W than those carrying R279H (Figure 1D). Taken together,
our RNA-seq analyses showed downregulation of epidermal
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differentiation genes and upregulation of non-epidermal genes in
p63 mutant keratinocytes, suggesting that p63 mutant keratino-
cytes have a less defined epidermal cell identity.
To better visualize the interaction between DE genes, we car-
ried out weighted gene-coexpression correlation network ana-
lyses using the Cytoscape Network Analyzer (Tables S1J and
S1K). Two significant coexpression modules were identified, of
which many genes were involved in keratinization (e.g., LOR
and FLG) and nucleosome assembly (Figures 1E and S2A; Table
S1L). Most genes in both modules showed downregulated
expression in p63 mutant keratinocytes. The upregulated genes
in p63 mutant keratinocytes did not generate significant main
modules but generated several small subnetwork modules.
They likely played roles in extracellular matrix organization
Figure 1. Transcriptome Dynamics of Control and p63 Mutant Keratinocytes during Differentiation
(A) EEC p63 mutant keratinocytes used in this study.
(B) The setup of in vitro differentiation of epidermal keratinocytes.
(C) Principal-component analysis (PCA) on RNA-seq data. Two independent control lines and three p63 mutant lines are indicated with different colors. Shapes
indicate four stages.
(D) Hierarchical clustering of differentially expressed genes (p < 0.05). The Z score was calculated based on log10 (fragments per kilobase per million reads
mapped [FPKM] + 0.01) of each gene. Enriched top two Gene Ontology (GO) terms of genes per gene expression cluster (EC) are shown.
(E) Coexpression network of deregulated genes in p63 mutant keratinocytes during differentiation. Interactions with connectivity weight > 0.1 were shown. Two
main co-expression modules were labeled with corresponding GO terms. The node color indicates the expression fold change between mutant and control
keratinocytes.
See also Figures S1 and S2 and Table S1.
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(Table S1L). However, the higher inter-modular connectivity be-
tween keratinization, nucleosome assembly, and extracellular
matrix organization modules suggests a biological relation-
ship between these modules, indicating that changes in the
chromatin landscape may contribute to gene deregulation.
Consistent with this notion, many chromatin regulators were
deregulated in p63 mutant keratinocytes (Figure S2B). These
factors include KAT2B, which is a histone acetyltransferase,
and SMYD3, which encodes a histone methyltransferase.
The deregulation of these genes was confirmed with qRT-PCR
(Figure S2C).
p63 Orchestrates Enhancer Dynamics during Epidermal
Differentiation
Given the indicated relationship between p63 and the chromatin
landscape, we first assessed the role of p63 in regulating the
chromatin landscape during normal epidermal differentiation.
We mapped histone modifications H3K27ac, H3K4me3, and
H3K27me3, as well as p63 binding sites (BSs) of control kerati-
nocytes, to open chromatin regions detected by DNase I hyper-
sensitivity sites (DHSs) in normal human epidermal keratinocytes
(NHEK) reported by ENCODE (Table S2). Two clusters of active
enhancers (C3 and C4) were bound by p63 (Figures S3A–S3C).
Regions in C3 showed higher p63-binding signals. GO annota-
tion using the Genomic Regions Enrichment of Annotation Tool
(GREAT), which permits functional interpretation of cis-regula-
tory regions (McLean et al., 2010), showed that nearby genes
were involved in apoptosis and epidermis development. Regions
in C4 had relatively lower p63-binding signals, and nearby genes
were involved in keratinocyte differentiation (Figure S3C).
Furthermore, cluster C7 represents a small group of open chro-
matin regions with H3K27me3 signals but devoid of p63 binding
(Figure S3A). Genes near these regions were associated with
‘‘pattern specification process,’’ such as neuron fate commit-
ment (Figure S3C).
To quantify chromatin dynamics, we used ChromHMM (Ernst
and Kellis, 2012) to analyze chromatin state transitions. With the
combination of H3K27ac, H3K4me3, and H3K27me3, we ob-
tained six classes of chromatin state: active enhancers, active
promoters, weak promoters, heterochromatin regions, bivalent
promoters, and ‘‘unmodified’’ regions that were not decorated
with any of the three modifications (Figure 2A; Tables S2B and
S2C). By pairwise comparison between two adjacent stages of
differentiation, we observedmajor transitions between active en-
hancers and unmodified regions as well as between unmodified
regions and heterochromatin regions (Figure 2B). As expected,
we found that the transition from unmodified regions to active
enhancers was generally associated with gene upregulation;
vice versa, the transition from active enhancers to unmodified re-
gions was associated with gene downregulation, at least at early
differentiation stages (days 0–2 and days 2–4) (Figure 2C), such
as regulation of LOR (Figure 2D) and KRT1 (Figure S3D). Further-
more, there were also transitions between active promoters and
unmodified regions (Figure S3E). Interestingly, many genes that
are known to be expressed in cells of mesodermal origin (e.g.,
PAX2) were heavily marked by H3K27me3 in proliferating kerati-
nocytes (day 0). The repression was relieved at the end of the ter-
minal differentiation of keratinocytes (Figure S3F).
Next, we asked whether specific TFs control enhancer dy-
namics during differentiation. Therefore, we performed motif
analysis of dynamic enhancers using the HOMER package (Fig-
ure 2E). We observed that bZIP, p53 or p63, Zinc finger (Zf), and
TEA motifs were enriched in regions being activated from un-
modified regions on day 0 to active enhancers on day 2, while
p53 or p63 was the only enrichedmotif in regions being activated
from unmodified regions on day 2 to active enhancers on day 4.
The bZIP motif was predominantly enriched in regions being
activated from unmodified regions on day 4 to active enhancers
on day 7, whereas the p53 or p63 motif was the only enriched
motif in regions changing from active enhancers on day 4 to un-
modified regions on day 7 (Figure 2E). The temporal enrichment
of p63 motifs in dynamic enhancers underscores the key role of
p63 in orchestrating the enhancer landscape during keratinocyte
differentiation.
Decreased Active Enhancers Associated with
p63-Binding Deficiency in p63 Mutant Keratinocytes
Based on the DNA-binding deficiency of EEC mutants shown by
various studies and the dominant-negative model, we expected
to detect DNA-binding loss in p63 mutant keratinocytes. To
characterize this and evaluate the effect of p63 mutations on
the enhancer landscape, we performed p63 chromatin immuno-
precipitation sequencing (ChIP-seq) using a p63 antibody that is
not affected by mutations in the p63 DNA-binding domain (Fig-
ure S4A) (Shen et al., 2013) and H3K27ac ChIP-seq in all three
p63 mutant keratinocytes. A total number of 33,366 p63-binding
sites (p63 BSs) detected in both control and mutant keratino-
cytes were analyzed, and we observed globally reduced p63
binding signals in p63 mutant keratinocytes as compared
to the control keratinocytes (Figure 3A; Tables S3A–S3E). It
should be noted that no clear increased p63 binding or
de novo p63 BSs were observed in p63 mutant keratinocytes.
K-means clustering analysis showed that p63 BSs can be clus-
tered into three groups based on the binding signals. Clusters
p63-C1 and p63-C2 had decreased p63 binding to a lesser
extent, whereas loci in p63-C3 showed more dramatic to almost
complete loss of p63-binding signals (Figure 3A). The p63-
binding pattern did not change much in mutant keratinocytes
during differentiation (Figure S4D). Accordingly, the difference
of H3K27ac signals at p63-C1 and p63-C2 between control
and p63 mutant keratinocytes was not obvious, whereas a
decrease of H3K27ac signals was detected at p63 C3 in p63
mutant keratinocytes (Figures 3A and S4B).
Using GREAT GO annotation to assess nearby genes, all three
clusters of p63 BSs were significantly enriched for genes
involved in epidermis development (Figure 3B). We also per-
formed human phenotype analyses to investigate the disease
significance of these p63 BSs, and the disease terms detected
were mainly related to ectodermal dysplasia, such as plantar hy-
perkeratosis, nail dystrophy, and alopecia (Figure S4C). We
further explored whether a specific molecular mechanism con-
trols the discordant p63-binding losses. We examined whether
the cooperation with different co-regulating TFs contributes to
the differential p63-binding loss by motif scanning but did not
find significant differential p63 co-regulators that can potentially
cause the discordant p63-binding loss (Tables S3H–S3J). Next,
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using our previously established p63scan algorithm (Kouwen-
hoven et al., 2010), we found that p63-C3 BSs sites had the
lowest percentage of BSs with the p63 motif (85%) and the
lowest average motif score (mean motif score of 8.3) compared
to p63-C1 (98%; mean motif score of 9.5) and p63-C2 (93%;
mean motif score of 8.8) BSs (Figure 3C; Tables S3K–S3N).
Our observations thus suggest that p63 motif strength deter-
mines the selectivity of the loss of p63 binding.
Lastly, we examined whether gene deregulation was associ-
ated with impaired p63 binding. Genes near p63 BSs (all three
[p63-C1, p63-C2, and p63-C3]) had a significantly larger pro-
portion of deregulated genes (34.8%, p = 0, hypergeometric
test) when compared to all annotated genes (12.5%) (Figure 3D;
Table S3F). A significant difference in the percentage of de-
regulated genes was also found in genes associated with
p63-C3 BSs (35.4%, p = 0, hypergeometric test) compared
to all genes with p63 BSs (Table S3G). These data indicate
A B C
D
E
Figure 2. Chromatin Dynamics during Con-
trol Keratinocyte Differentiation
(A) Emission states of the ChromHMM hidden
Markov model distinguishing six combinations
defined by three histone modifications: H3K27ac,
H3K4me3, and H3K27me3. ‘‘Unmodified regions’’
refers to genomic regions that do not have any of
these modifications.
(B) Alluvial plots of pairwise chromatin state tran-
sitions during differentiation. The column height
represents the percentage of each of the chro-
matin state relative to the sum of the six states.
Genomic regions defined as unmodified regions at
all differentiation stages were excluded in this
analysis. The percentages of active enhancers,
unmodified regions, and the heterochromatin are
labeled.
(C) Pairwise comparison of differential gene
expression (fold change) associated with genomic
regions that shift between unmodified regions and
active enhancers during differentiation, corre-
sponding to (B). Data are shown as mean ± SD;
**p < 0.01, and ***p < 0.001, unpaired t test.
(D) Chromatin state dynamics of unmodified re-
gions and active enhancers during differentiation
at the locus of LOR.
(E) Significantly enriched motifs in the dynamic
enhancer regions. Red dots, motifs that were en-
riched in regions shifting from unmodified regions
to active enhancers; blue dots, motifs that were
enriched in regions shifting from active enhancers
to unmodified regions.
See also Figure S3 and Table S2.
that impaired p63 binding significantly
contributed to deregulated gene expres-
sion, for both up- and downregulation
(Figure 3E).
In summary, we showed that EEC mu-
tations can result in loss of p63 binding
and loss of active enhancers. The loss of
p63 binding is apparently motif-strength
dependent. p63-binding loss can lead
to gene deregulation and potentially contribute to ectodermal
dysplasia phenotypes.
Redistribution of Enhancers in p63 Mutant
Keratinocytes
Although a significant percentage of deregulated genes (54%)
were associated with impaired p63 binding, a large number of
deregulated genes did not seem to be directly regulated by
p63. Furthermore, we observed many enhancers with unex-
pected increased H3K27ac signals near deregulated genes in
p63 mutant keratinocytes (Figure 4A, blue shaded regions).
Therefore, we compared H3K27ac between control and p63
mutant keratinocytes with MAnorm (Shao et al., 2012). We iden-
tified 17,931 genomic regions that had significantly higher
H3K27ac signals in mutant keratinocytes (referred to as
mutant-specific enhancers), which is more than the 15,057
regions that had significantly higher H3K27ac in control
3494 Cell Reports 25, 3490–3503, December 18, 2018
keratinocytes (referred to as control-specific enhancers) (Figures
S5A and S4B; Table S4). Two replicas of H3K27ac ChIP-seq
in R304W mutant keratinocytes showed a high correlation
(Pearson correlation coefficient of 0.94; Figure S5B), demon-
strating the high reproducibility of these datasets. To validate
these findings, H3K27ac ChIP-qPCR was performed on three
Figure 3. Decreased Active Enhancers Associated with p63-Binding Deficiency
(A) K-means clustering of p63-binding sites (BSs) that are merged from control and p63 mutant keratinocytes groups p63 BSs into 3 classes (k = 3, metric =
Pearson). Heatmaps and band plots are shown in a 4-kb window with summits of p63 BSs in the middle. Color intensity in heatmaps represents normalized read
counts. In the band plots, the median enrichment was visualized as the black line while 50% and 90% ranges were depicted in lighter color, respectively.
(B) GREAT-based GO biological process annotation of p63 BSs in each cluster.
(C) p63 motif strength determined the selectivity of the loss of p63 binding. Top: pie charts showing the percentage of p63 BSs with a p63 motif. Bottom: boxplot
showing motif score distribution. Data are shown as mean ± SD; ***p < 0.001, one-way ANOVA.
(D) Percentage of deregulated genes associated with all p63 BSs and p63 BSs from p63-C3 (p63 C3) compared with all annotated genes. ***p < 0.001, hy-
pergeometric test.
(E) ChIP-seq of p63 and RNA-seq data at the RUNX1, EHF, SMYD3, and KAT2B loci in control and p63 mutant keratinocytes. Red bars represent p63 BSs that
were lost or decreased in p63 mutant keratinocytes.
See also Figure S4 and Table S3.
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control-specific and three mutant-specific enhancer loci (Fig-
ure S5C). Genes nearby control-specific enhancers were associ-
ated with keratinocyte differentiation, whereas those nearby
mutant-specific enhancers were involved in cell-cycle regula-
tion, migration, and non-epithelial processes (Figure 4C).
Furthermore, a significantly larger proportion of deregulated
genes had either control-specific or mutant-specific H3K27ac
sites (Figure 4D). As expected, control-specific enhancers
were associated with gene downregulation, whereas mutant-
specific enhancers were associated with gene upregulation in
p63 mutant keratinocytes (Figure 4E). Taken together, the
observed genome-wide redistribution of enhancers marked by
H3K27ac indicates that epigenome rewiring occurs in p63
mutant keratinocytes.
To investigate the underlying mechanisms of enhancer re-dis-
tribution, a de novomotif scan was performed. We detected the
p53 or p63 motif family as the top enriched motif among control-
specific enhancers (Figure 4F; Table S4I), consistent with the
Figure 4. Redistribution of Enhancers in p63 Mutant Keratinocytes
(A) Examples of redistributed enhancersmarked byH3K27ac signals between control and p63mutant keratinocytes. Black boxes indicate lost p63 BSwith lost or
decreased H3K27ac signals. Blue shades indicate gained enhancers in p63 mutant keratinocytes.
(B) Heatmaps of differential H3K27ac peaks in control and p63mutant keratinocytes shown in a 4-kbwindowwith summits of H3K27ac peaks in themiddle. Color
intensity in heatmaps represents normalized read counts.
(C) GREAT-based GO biological process annotation of differential enhancers.
(D) Percentage of deregulated genes relative to all genes associated with active enhancers, all or control- or mutant-specific enhancers. ***p < 0.001, hyper-
geometric test.
(E) Differential gene expression (fold change) associated with control or mutant-specific enhancers. Data are shown as mean ± SD; ***p < 0.001, unpaired t test.
(F) Highly enriched motifs found in control-specific or mutant-specific enhancers.
See also Figure S5 and Table S4.
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impaired p63 binding and loss of active enhancers in p63 mutant
keratinocytes (Figure 3A). In contrast, motif analyses of mutant-
specific enhancers captured motifs of bZIP, TEA, high-mobility
group (HMG), and Runt family TFs (Table S4M). These data sug-
gest that aberrant recruitment of TFs induces gain of enhancers.
One scenario of aberrant recruitment of TFs may result from
the abnormal upregulation of TFs in mutant keratinocytes. To
assess this possibility, we examined differential expression of
TFs. Among 1,581 examined TFs (Saeed et al., 2014), 106 and
103 TFs were down- and upregulated, respectively, in p63
mutant keratinocytes (Figure S6). Interestingly, most downregu-
lated TFs had p63 BSs nearby and therefore are potential p63
direct targets. In contrast, fewer upregulated TFs had p63 BSs.
To predict candidate TFs that are potentially bound to mutant-
specific enhancers, we used two criteria: (1) TFs whose binding
motifs were enriched in mutant-specific enhancers (Figure 4F),
and (2) TFs that were upregulated in all three p63 mutant kerati-
nocytes at the proliferation stage (day 0) (Figure S6A). Among
TFs that were consistently upregulated in mutant keratinocytes,
RUNX1 and SOX4 belong to the TF families whose motifs were
enriched in mutant-specific enhancers. We performed qRT-
PCR validation to confirm the higher expression of SOX4 in
p63 mutant keratinocytes (Figure S6B). ChIP-qPCR of SOX4
also confirmed a number of SOX4 BSs with higher binding sig-
nals in R304Wmutant keratinocytes compared to control kerati-
nocytes (Figure S6C). Interestingly, one of the candidate TFs
RUNX1 is a known p63 target (Masse et al., 2012) and a potential
p63 co-regulator. RUNX1 had many lost p63 BSs in the gene lo-
cus and was consistently upregulated in p63 mutant keratino-
cytes (Figures 3E and S6A).
Deregulated p63 and RUNX1 Cooperation Contributes
to Transcriptional Rewiring inMutant p63Keratinocytes
To characterize p63 and RUNX1 co-regulation, we performed
RUNX1 ChIP-seq in control keratinocytes. K-means clustering
of RUNX1 BSs in combination with p63 binding and histone
modification profiles showed that RUNX1 and p63 preferentially
co-bound in active enhancer regions (Figure 5A). RUNX1 bound
more frequently to active promoters marked by H3K4me3
(RUNX1-C4) than p63 (RUNX1-C1 and RUNX1-C3) (Figure 5A;
Table S5A). Genes near the co-regulated enhancers (RUNX1-
C1 andRUNX1-C3 [e.g., ITGB1 and EGFR]) weremainly involved
in epidermis development and programmed cell death, respec-
tively (Figures 5B and 5C). The observed upregulation of
RUNX1 expression (Figure 5D) and loss of p63 binding in the
RUNX1 gene body in p63 mutant keratinocytes (Figure 3E) indi-
cated that deregulation of RUNX1 expression is probably due to
loss of p63 control. To further confirm this, we performed small
interfering RNA (siRNA) knockdown of p63 in control keratino-
cytes. Similar to the upregulated RUNX1 expression in p63
mutant keratinocytes, RUNX1 expression was significantly
increased in p63 knockdown keratinocytes (Figure 5E).
To assess whether upregulatedRUNX1 expression leads to its
aberrant recruitment tomutant-specific enhancers in p63mutant
keratinocytes, we compared RUNX1 binding in control keratino-
cytes and R304Wmutant keratinocytes (Figure 6A; Tables S5B–
S5D). Among all RUNX1 BSs, there were 7,918 RUNX1 BSs with
higher binding signals and 7,898 sites with lower binding signals
in R304W mutant keratinocytes (Tables S5B–S5F). RUNX1 BSs
with increased binding signals in R304W mutant keratinocytes
were more often located in active enhancer regions accompa-
nied by increased H3K27ac signals (Figure 6B; Table S5E), while
those with decreased RUNX1-binding signals were more often
located in promoter regions (Figures S7A and S7B; Table S5F).
To test whether increased RUNX1 expression is responsible
for deregulating gene expression in p63 mutant keratinocytes,
we performed RUNX1 knockdown in R304W mutant keratino-
cytes. As the proper RUNX1 expression level is important for
cell proliferation (Hoi et al., 2010;Masse et al., 2012), we carefully
titrated RUNX1 siRNA oligonucleotides to achieve a level of
RUNX1 expression similar to that in control keratinocytes.
RNA-seq analyses showed that the overall gene expression of
siRUNX1-treated R304Wmutant keratinocytes was more similar
to that of control keratinocytes in PCA (Figure S7C). Among the
3,294 upregulated genes in R304W mutant keratinocytes, 276
genes were significantly rescued downregulated upon siRUNX1
(Figure 6C; Tables S5H and S5I), such as KRT8 (Figure S7E).
Many of the rescued genes were involved in adhesion and other
non-epithelial functions, such as angiogenesis. Importantly,
among the 3,187 downregulated genes in R304Wmutant kerati-
nocytes, 218 genes were significantly rescued, with upregulated
expression upon siRUNX1 (Figure 6D; Tables S5J and S5K),
such as KRT1 and HES5 (Figures 6E and S7D). Many of these
genes are important for epidermal development and keratino-
cyte differentiation. The number of rescued genes was signifi-
cantly higher than random expectations (276/3,294, hypergeo-
metric test p < 7.272e102; 218/3,184, hypergeometric test
p < 4.305e54). Partial but significant rescues by siRUNX1
were expected, as deregulated genes caused by loss of p63
binding in p63mutant keratinocytes could not be rescued simply
by RUNX1 knockdown. qRT-PCR and western blotting experi-
ments validated rescued gene expression of KRT1, SMYD3,
and KRT18 in R304W mutant keratinocytes upon siRUNX1 (Fig-
ures 6F and 6G). To further investigate whether siRUNX1 can
rescue the enhancer landscape in R304Wmutant keratinocytes,
we performed H3K27ac ChIP-seq in these cells. Indeed, we
observed a clear decrease of H3K27ac signals at enhancers
that had higher H3K27ac signals and bound by RUNX1 in p63
mutant keratinocytes (Figure 6B; n = 6,035) in two biological rep-
licas (Figures 6H and S7E), such as enhancers nearNRP1, which
is involved in angiogenesis (Figure 6I). Taken together, our data
suggest that reversing upregulated RUNX1 expression can
rescue deregulated gene expression and the enhancer land-
scape in p63 mutant keratinocytes.
DISCUSSION
The master regulator role of p63 in epidermal development has
been established by many studies using in vitro and in vivo
models. However, it remains unclear how p63 mutations affect
the chromatin landscape and gene expression that contribute
to diseases. In this study, we used EEC-patient-derived skin
keratinocytes carrying heterozygous p63 DNA-binding domain
mutations as the cellular model to characterize the global gene
regulatory alteration. We showed that the epidermal cell identity
was compromised in p63 mutant keratinocytes, as indicated by
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downregulated epidermal genes and upregulated non-epithelial
genes. In addition to loss of p63 binding leading to reduced p63-
bound active enhancers, we unexpectedly observed abnormally
induced active enhancers that were bound by upregulated p63
co-regulators such as RUNX1. Reversing RUNX1 upregulation
in p63 mutant keratinocytes rescued a part of the deregulated
gene expression and altered enhancer landscape. Our data sug-
gest an intriguing model whereby rewiring of the enhancer land-
scape, contributed by both loss of p63-bound active enhancers
and gain of active enhancers induced by overexpressed p63 co-
regulators, gives rise to gene deregulation and phenotypes of
EEC syndrome (Figure 7).
Many epidermal genes were downregulated in mutant kerati-
nocytes, consolidating the key role of p63 in epidermal develop-
ment. In addition, upregulated mesenchymal genes and
neuronal genes in mutant keratinocytes (Figure 1D) suggest
that these cells have less defined epidermal cell fate. For
example, mesodermal related genes such as ACTA2 and
COL4A1, whichwere upregulated during epidermal commitment
of p63-depeleted embryonic stem cells (Shalom-Feuerstein
et al., 2011), were also upregulated in p63 mutant keratinocytes
(Table S1E). In agreement, gene coexpression network analyses
showed that the scattered upregulated genes involved in extra-
cellular matrix organization were connected with two modules
(keratinization and nucleosome assembly) associated with
downregulated genes in mutant keratinocytes (Figure 1E). This
suggests that gene expression in p63 mutant keratinocytes de-
viates fom the proper epidermal cell fate to establish a new dif-
ferentiation direction through chromatin remodeling processes.
In addition to directly regulating chromatin remodeling factors
(Figure S2B), we showed in this study that p63 motif was most
significantly enriched in active enhancers at early differentiation
A B
C D E
Figure 5. RUNX1 Is a Co-regulator and Target Gene of p63
(A) K-means clustering of RUNX1 BSs in control keratinocytes. RUNX1-binding signals are shown in heatmaps in a 4-kb window with summits of RUNX1 BSs in
the middle (k = 4, metric = Pearson). Color intensity represents normalized read counts.
(B) GREAT-based GO biological process annotation of RUNX1 BSs in RUNX1 C1 and C3.
(C) Representative example of RUNX1 and p63-co-regulated genes ITGB1 and EGFR.
(D) Validation ofRUNX1 gene expression by qRT-PCR and western blotting. In qRT-PCR analysis, relative gene expression was normalized to the reference gene
hARP. Data are shown as mean ± SD, technical replicates n = 2; NS, p > 0.05; ***p < 0.001, two-way ANOVA. Actin was used as a loading control for the
quantification of RUNX1 protein levels (shown as percentage) in western blotting.
(E) Gene expression analysis by qRT-PCR of TP63 and RUNX1 expression in TP63 knockdown (siTP63) compared to non-targeting siRNA (siNT) in control
keratinocytes. Gene expression was normalized to the reference gene hARP. Data are shown as mean ± SD, technical replicates n = 2; ***p < 0.001, two-way
ANOVA.
See also Figure S6 and Table S5.
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Figure 6. Increased RUNX1 Binding Contributes to Gene Deregulation
(A) K-means clustering of RUNX1 BSs from control and R304W mutant keratinocytes are shown in heatmaps in a 4-kb window with summits of merged RUNX1
BSs in the middle (k = 2, metric = Pearson). Color intensity represents normalized read counts.
(B) Zoom-in re-clustering of increasedRUNX1BSs in R304Wmutant keratinocytes showing that themajority of RUNX1BSswith increased signals are enhancers.
(C) 276 significantly upregulated genes in R304Wmutant keratinocytes that were rescued with siRUNX1 (p < 0.05). The significance of the overlap was calculated
using a hypergeometric test (p < 7.272e-102). Expression (RNA-seq FPKM) of rescued genes under different conditions is shown as mean ± SD. ***p < 0.001,
t test. DAVID-based GO biological process annotation is shown at the bottom.
(D) 218 significantly downregulated genes in R304W mutant keratinocytes that were rescued with siRUNX1 (p < 0.05). The significance of the overlap was
calculated with hypergeometric test (p < 4.305e-54).
(E) UCSC genome browser screenshots of RNA-seq data at the gene loci of KRT1 and KRT8 are shown as examples of rescued genes by siRUNX1.
(F) Gene expression analyses by qRT-PCR of RUNX1, KRT1, and SMYD3. Relative gene expression of these genes was normalized to the reference gene hARP.
Data are shown as mean ± SD, technical replicates n = 2; *p < 0.1, **p < 0.01, ***p < 0.001, two-way ANOVA.
(legend continued on next page)
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stages (Figure 2E). These results support the pivotal role of p63 in
regulating enhancers to activate epidermal differentiation genes,
especially at the initiation stage.
In addition to its activator role for epidermal genes, it has been
shown that p63 can function as a repressor to repress p21
(CDKN1A) through recruiting histone deacetylase 1 (HDAC1)
and HDAC2 (LeBoeuf et al., 2010; Ramsey et al., 2011).
RUNX1, a co-regulator of p63, is regulated by p63 in a complex
fashion. Depending on the differentiation state of keratinocytes,
p63 activates or represses RUNX1 expression (Masse et al.,
2012). In our analyses, we detected upregulation of RUNX1 in
proliferating mutant keratinocytes (Figures 3E and 5D), consis-
tent with the repressor role of p63 for these genes. However,
p63-bound enhancers at the RUNX1 locus were active en-
hancers, marked by H3K27ac, in contrast to classically defined
repressed regions that are marked by H3K27me3 and
H3K9me3. Furthermore, no H3K27me3 or H3K9me3 repression
mark was found at any p63 BS (Kouwenhoven et al., 2015a), indi-
cating that p63-bound enhancers are not repressed by poly-
comb- or heterochromatin-related mechanisms. To reconcile
the apparent contradiction that p63 binds to active enhancers
to repress gene expression, we speculate that p63 binds to
these active enhancers to fine-tune expression of these genes
by recruiting repressors such as HDACs. When p63 expression
or function is compromised, such as in p63mutant keratinocytes
or p63 knockdown cells (Figures 5D and 5E), the fine-tuning or
repression mechanisms are relieved, and the expression of
these genes is enhanced (Figure 7B).
In this study, we showed that p63-binding loss and loss of
active enhancers occurs at a genome-wide scale in patient ker-
atinocytes carrying heterozygous EEC mutations (Figure 3A).
This indicates that the mutant p63 protein has a dominant-nega-
tive effect on DNA binding over the wild-type p63 that is also pre-
sent in the cell, likely because the p63 protein is DNA-binding
competent as a tetramer (Do¨tsch et al., 2010; Serber et al.,
2002). These genome-wide findings corroborate the dominant-
negative model of EEC p63 mutations that has been proposed
by several previous studies using in vitro approaches and
allele-specific knockdown of p63 mutant.
Unexpectedly, we observed a large number of gained active
enhancers in all three p63 mutant keratinocytes (Figures 4A,
4B, and S5A). These mutant-specific enhancers were enriched
for motifs of TFs that normally cooperate with p63 in keratino-
cytes (Figure 4F). Many of these TFs were deregulated in p63
mutant keratinocytes (Figure S6) and are direct p63 targets,
such as RUNX1 (Figures 3E and 5D). This indicates that rewiring
of the transcriptional program is caused not only by loss of
p63-bound active enhancers but also by an indirect effect
of altered expression of p63 co-regulating TFs. ChIP-seq ana-
lyses revealed an altered RUNX1-binding profile in p63 mutant
(G) Western blotting analysis of RUNX1 and KRT18 in control and R304W mutant keratinocytes and in R304W keratinocytes treated with siRNA oligos. The
RUNX1 knockdownwas tested with two siRUNX1 oligos. The informative siRUNX1 oligo resulted in approximately 50% knockdown of RUNX1 at the protein level
in R304W keratinocytes, as compared to the non-targeting oligo (NT). The blot with the non-informative siRUNX1 oligo without clear RUNX1 knockdown is
included in Table S6. The protein samples were first titrated by western blotting of Actin and equal amounts were loaded for RUNX1 and KRT18 analyses. All
western blots of the complete experiment are labeled and shown in Table S6.
(H) Decreased H3K27ac signals upon siRUNX1 treatment at the enhancers that had higher signals in R304W mutant keratinocytes (enhancer regions in B).
(I) An UCSC genome browser screenshot at the gene locus of NRP1, to show rescued enhancers, highlighted in pink.
See also Figure S7 and Table S5.
Figure 7. Model of p63-Controlled Gene Regulation and Cell Identity in Control and p63 Mutant Keratinocytes
(A) p63-mediated activation of epidermal genes. In control keratinocytes, p63 activates epidermal genes by binding to nearby active enhancers, in cooperation
with co-regulating TFs and chromatin factors (CFs). In p63 mutant keratinocytes, mutant p63 cannot bind to these enhancers, which results in downregulation of
epidermal genes.
(B) p63-mediated fine-tuning of its co-regulators. In control keratinocytes, p63 fine-tunes the expression of its co-regulators, such as RUNX1 and SOX4. In p63
mutant keratinocytes, mutant p63 cannot bind to these enhancers and loses fine-tuning control.
(C) Indirect activation of enhancers due to lack of p63 control. Overexpressed p63 co-regulators such as RUNX1 can bind to less controlled open chromatin
regions and enhancers to activate non-epidermal genes in p63 mutant keratinocytes.
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keratinocytes (Figure 6A). The increased RUNX1 binding was
associated with increased H3K27ac signals (Figure 6B). Intrigu-
ingly, reversing RUNX1 expression upon siRUNX1 could partially
rescue gene deregulation and the enhancer landscape (Figures
6C–6I), indicating that overexpression of RUNX1 in mutant kera-
tinocytes contributes to gene deregulation and is at least partially
responsible for the differentiation defects. Therefore, mutations
in the p63 DNA-binding domain can give rise to an indirect
gain-of-function effect by inducing aberrant binding of deregu-
lated TFs to genome-wide enhancers (Figure 7C).
It should be noted that this gain-of-function model of p63 EEC
mutations is different from the gain-of-function mechanism of a
p63 mutation leading to phenotypically distinct Acro-dermato-
ungual-lacrimal-tooth (ADULT) syndrome (Rinne et al., 2007)
and p53 mutations that give rise to cancers. It has been shown
that some p53 mutants involved in cancer cannot bind to bona
fide p53 targets, but cooperate with normal p53 co-regulators
and bind to ectopic genomic sites to activate abnormal gene
expression (Zhou et al., 2014; Zhu et al., 2015), a classical para-
digm of gain of function. The most apparent difference between
p53 and p63 EEC mutations is that EEC mutant p63 does not
seemingly bind to ectopic genomic loci, as we did not observe
any novel p63 BS in mutant keratinocytes (Figure 3A). The indi-
rect gain-of-function action of p63 mutations is due to the over-
expression of p63-co-regulating TFs, such as RUNX1, and their
aberrant recruitment to mutant-specific enhancers.
In the siRUNX1 experiment, we did not expect a full rescue in
p63 mutant keratinocytes, as p63-binding loss could not simply
be rescued by RUNX1 downregulation. With the same rationale,
we also do not expect that overexpression of RUNX1would fully
mimic p63 mutant keratinocyte phenotypes. However, it would
be interesting to test whether overexpression of RUNX1 in
control keratinocytes can induce any differentiation defects.
Furthermore, it is also of interest to further test the effect of other
overexpressed p63 co-regulators such as TFs of the bZIP, TEA,
and HMG families (SOX4) (Figure 4F) in the EEC disease mech-
anism. It is conceivable that knockdown of multiple such overex-
pressed TFs may rescue differentiation defects of p63 mutant
keratinocytes to a better extent.
In conclusion, we identified a rewired enhancer landscape as a
common mechanism in EEC p63 mutant keratinocytes. The
enhancer rewiring includes loss of p63-bound active enhancers
that regulate epidermal genes (Figure 7A) and gain of enhancers
bound by overexpressed TFs that are normally fine-tuned by p63
(Figures 7B and 7C). It is conceivable that in EEC p63mutant ker-
atinocytes, the chromatin environment is less tightly controlled,
and deregulated TFs can therefore bind to more exposed en-
hancers. The rewired enhancer landscape gives rise to gene
deregulation that contributes to the less-defined epidermal cell
fate and skin phenotypes of the disease. Taken together,
enhancer landscape rewiring contributes to the disease mecha-
nism of p63 mutation and may be common to many other
diseases.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-b-Actin antibody, Mouse monoclonal Sigma-Aldrich Cat#A1978, clone AC-15
Anti-LOR Babco COVANCE Cat#PRB-145P
Anti-RUNX1 Abcam Cat#ab23980; RRID:AB_2184205
Anti-K18 Merck Cat#MAB3234
Anti-H3K27ac Diagenode Cat#C15410174; RRID:AB_2716835
Anti-H3K4me3 Diagenode Cat#C15410003
Anti-H3K27me3 Diagenode Cat#C15410069
Anti-p63 Santa Cruz Cat#H129
Chemicals, Peptides, and Recombinant Proteins
Keratinocyte Basal Medium Lonza Cat#CC-4131
Penicillin/Streptomycin GIBCO Life Technology Cat#15140122
ethanolamine Sigma Aldrich Cat#141-43-5
O-phosphoethanolamine Sigma Aldrich Cat#1071-23-4
BPE(bovine pituitary extract) Lonza Cat#CC-4131
hydrocortisone Lonza Cat#CC-4131
insulin Lonza Cat#CC-4131
EGF(epidermal growth factor) Lonza Cat#CC-4131
USER enzyme BioLab Cat#M5505L
Critical Commercial Assays
NucleoSpin RNA kit MACHEREY-NAGEL Cat#740955.250
iScript cDNA synthesis kit Bio-Rad Cat#170-8891
iQ SYBR Green Supermix Bio-Rad Cat#1708887
MinElute Reaction Cleanup Kit QIAGEN Cat#28206
KAPA Hyper Prep Kit Kapa Biosystems Cat#KK8504
KAPA Library Quantification Kit Kapa Biosystems Cat#KK4844
Deposited Data
Raw and analyzed data from control keratinocytes This paper GEO accession GSE98483
Raw and analyzed data from EEC keratinocytes This paper dbGaP accession ID phs001737.v1.p1
Oligonucleotides
RT-qPCR primers Biolegio BV, Nijmegen,
the Netherlands
Provided in Table S1C
siRNA Thermo Fisher scientific Provided in Table S5G
Software and Algorithms
STAR 2.5.0 Dobin et al., 2013 https://github.com/alexdobin/STAR
DESeq2 Love et al., 2014 https://bioconductor.org/packages/release/
bioc/html/DESeq2.html
WGCNA Langfelder and Horvath, 2008 https://horvath.genetics.ucla.edu/html/
CoexpressionNetwork/Rpackages/WGCNA/
Cytoscape Smoot et al., 2011 https://cytoscape.org/
BWA Li and Durbin, 2009 http://bio-bwa.sourceforge.net/bwa.shtml
MACS2 Zhang et al., 2008 https://github.com/taoliu/MACS
MAnorm Shao et al., 2012 https://manorm.readthedocs.io/en/latest/
fluff Georgiou and van Heeringen,
2016
https://fluff.readthedocs.io/en/latest/
usage.html
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Huiqing
Zhou (j.zhou@science.ru.nl; jo.zhou@radboudumc.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human primary keratinocyte
All procedures for establishing and maintaining human primary keratinocytes were approved by the ethical committee of the Rad-
boud university medical center (‘‘Commissie Mensgebonden Onderzoek Arnhem-Nijmegen’’). Informed consent was obtained
from all donors of a skin biopsy. Primary keratinocytes were established previously from skin biopsies of three EEC syndrome pa-
tients carrying heterozygous mutations in the p63 DNA-binding domain, R204W (van Bokhoven et al., 2001), R279H (van Bokhoven
and Brunner, 2002), and R304W (Celli et al., 1999), as well as of two healthy volunteers (Dombi23 and PCK19, referred to as Control)
(Rheinwald and Green, 1977). Sex of the control keratinocytes is unknown because they are derived from the anonymous donors.
METHOD DETAILS
Cell culture
Primary keratinocytes were cultured in Keratinocyte Basal Medium supplemented with 100 U/mL Penicillin/Streptomycin, 0.1 mM
ethanolamine, 0.1 mM O-phosphoethanolamine, 0.4% (vol/vol) bovine pituitary extract, 0.5 mg/mL hydrocortisone, 5 mg/mL insulin
and 10 ng/mL epidermal growth factor. Medium was refreshed every other day. When cells were more than 90% confluent (day 0),
differentiation was induced by depletion of growth factors in addition to cell contact inhibition, as described previously (Van Ruissen
et al., 1996). Cells were collected at four differentiation stages, proliferation (day 0), early differentiation (day 2), mid differentiation
(day 4), and late differentiation (day 7) for subsequent experiment. No mycoplasma contamination is found during cell culture.
RNA extraction and quantitative real-time reverse transcription PCR (RT–qPCR)
Total RNAwas isolated using the NucleoSpin RNA kit and quantified with NanoDrop. cDNA synthesis from 1 mg freshly prepared total
RNA was carried out using the iScript cDNA synthesis kit. Reverse transcription quantitative PCR (RT-qPCR) primers were designed
using Primer3 to obtain exon spanning primers wherever possible. Each primer set has been tested for its linear amplification dy-
namic range. RT-qPCRs were performed in the CFX96 Real-Time system (Bio-Rad) by using iQ SYBR Green Supermix according
to the manufacturer’s protocol. The human acidic ribosomal protein (hARP) or glucuronidase beta (GusB) was used as the house-
keeping gene for normalization. Differences in the expression of each gene during differentiation (relative expression) were calculated
by 2DDCt method (Livak and Schmittgen, 2001). Sequences of all RT-qPCR primers were provided in Table S1C.
Western blotting
A total of 12.5 mg protein was loaded for each sample. The actin antibody (1:100,000) was used to control equal protein loading.
Protein extracts were run on SDS-PAGE and transferred to PVDF membranes using the NuPAGE system (Life Technologies).
LumiGLO (Cell Signaling Technology Inc.) was used for chemiluminescent detection by the Bio-Rad Universal Hood Gel Imager
(Bio-Rad Laboratories). Antibodies used in this study include LOR (1:2500), RUNX1 (1:50), K18 (1:500). All the original blots were pro-
vided in Table S6.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
deepTools Ramı´rez et al., 2014 https://deeptools.readthedocs.io/en/develop/
ChromHMM Ernst and Kellis, 2012 http://compbio.mit.edu/ChromHMM/
p63scan Kouwenhoven et al., 2010 N/A
HOMER N/A http://homer.ucsd.edu/homer/motif/
GraphPad Prism N/A https://www.graphpad.com/scientific-
software/prism/
Other
Primer3 N/A http://bioinfo.ut.ee/primer3-0.4.0/
DAVID Huang da et al., 2009 https://david.ncifcrf.gov/
GREAT McLean et al., 2010 http://great.stanford.edu/public/html/index.php
Sankey diagrams N/A http://sankeymatic.com/
GeneProf N/A https://bio.tools/geneprof
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RNA-seq and analysis pipeline
RNA-seq experiment was performed as described previously (Kouwenhoven et al., 2015a) with the starting material of 500 ng total
RNA, to obtain double-strand cDNA (ds-cDNA). After purification with the MinElute Reaction Cleanup Kit, 3 ng ds-cDNA was pro-
cessed for library construction using KAPA Hyper Prep Kit according to the standard protocol except that a 15-minute USER enzyme
incubation step was added before library amplification. The prepared libraries were quantified with the KAPA Library Quantification
Kit, and then sequenced in a paired-ended manner using the NextSeq 500 (Illumina) according to standard Illumina protocols.
Sequencing reads were aligned to human genome assembly hg19 (NCBI version 37) using STAR 2.5.0 (Dobin et al., 2013) with
default options. A detailed summary of RNA-seq data generated in this study was shown in Table S6A. For data visualization, wig-
ToBigWig from the UCSC genome browser tools was used to generate bigwig files and uploaded to UCSC genome browser. Genes
with the mean of DESeq2-normalized counts (‘‘baseMean’’) > 10 were considered to be expressed. Differential gene expression
(adjusted P value < 0.05) and principal-component analysis were performed with the R package DESeq2 using read counts per
gene (Love et al., 2014). Hierarchical clustering was performed based on log10 (FPKM+0.01). Functional annotation of genes was
performed with DAVID (Huang da et al., 2009). For Weighted Gene Co-expression Network Analysis (WGCNA (Langfelder and Hor-
vath, 2008)), only high variance genes (adjusted P value < 0.01, sum of baseMean > 100, 3162 genes) between control keratinocytes
and p63 mutant keratinocytes during differentiation were included. WGCNA clustering within p63 mutant keratinocyte samples was
performed using power of 26 and theminimummodule size of 15. A total of 16 co-expression modules were identified based on gene
co-expression patterns (Table S1J). To visualize the gene network organization, only nodes (genes) with connectivity weight > 0.1
were kept (Table S1K). Cytoscape (Smoot et al., 2011) was used for gene network visualization.
ChIP-seq and analysis pipeline
Chromatin for ChIP was prepared as previously described(Kouwenhoven et al., 2010). ChIP assays were performed following a stan-
dard protocol (Novakovic et al., 2016) with minor modifications. Antibodies against H3K27ac (1.2 mg), H3K4me3 (1 mg), H3K27me3
(1.5 mg), p63 (1 mg, recognizing the C-terminal a tail of p63) and RUNX1 (4 mg) were used in each ChIP assay. Resulted DNA fragments
from four independent ChIP assays were purified and subjected to a ChIP-qPCR quality check. Afterward 5ng DNA fragments were
pooled and proceeded on with library construction using KAPA Hyper Prep Kit according to the standard protocol. The prepared
libraries were then sequenced using the NextSeq 500 (Illumina) according to standard Illumina protocols.
Sequencing reads were aligned to human genome assembly hg19 (NCBI version 37) using BWA (Li and Durbin, 2009). Mapped
reads were filtered for quality, and duplicates were removed for further analysis. A detailed summary of ChIP-seq data generated
in this study was shown in Table S6B. In addition. The bamCoverage script was used to generate and normalize bigwig files with
the RPKM formula. The peak calling was performed with the MACS2 (Zhang et al., 2008) against a reference input sample from
the same cell line with standard settings and a q value of 0.05. Only peaks with a P value < 10e-5 were used for differential analysis
with MAnorm (Shao et al., 2012). Association of peaks to genes and associated GO annotation were performed with GREAT (McLean
et al., 2010). P values were computed with a hypergeometric distribution with FDR correction. k-means clustering and heatmap and
band plot generation were carried out with a Python package fluff (Georgiou and van Heeringen, 2016). H3K27ac ChIP-seq analyses
of control and mutant keratinocytes, including those performed in siRUNX1 experiments, were performed in duplicates. The ‘plot-
Correlation’ function from the deepTools package was used and the Pearson correlation coefficient was calculated accordingly
(Ramı´rez et al., 2014).
ChomHMM analysis
Chromatin states were characterized using ChromHMM v1.11 (Ernst and Kellis, 2012). The peak files from three tracks (H3K27me3,
H3K4me3, and H3K27ac) across four stages were used as input. The six-emission state model was determined to be optimal which
could sufficiently capture the biological variation in co-occurrence of chromatin marks. The segmentation files of the six emission
states per stage were binned into 200 bp intervals. AnM3Nmatrix was created, where M corresponds to the 200 base pair intervals
and N to the developmental stages (N = 4). Each element x (m, n) represents the chromatin state of interval m at stage n. For each
chromatin group, occurrences were counted per stage N (Table S2C). The changes between stage N and N+1 were plotted pairwise
using Sankey diagrams (http://sankeymatic.com/).
Motif analysis
Previously described p63scan algorithm was used for p63 motif evaluation(Kouwenhoven et al., 2010). HOMER (http://homer.ucsd.
edu/homer/motif/) was used for motif scan against corresponding background sequences.
siRNA nucleofection
Nucleofection was performed as described previously (Mulder et al., 2012) using the Amaxa 96-well shuttle system (Lonza, program
FF113). In short, keratinocytes were harvested with Accutase solution and resuspended in nucleofector buffer SF (Lonza). Each
20 mL transfection reaction contained 200,000 cells mixed with 2 mM validated siRNA (Silencer Select siRNAs, Ambion/Applied Bio-
systems). In siRUNX1 experiments, siRUNX1-1 oligo was used for the RNA-seq experiment and siRUNX1-2 oligo was used for the
western blot experiment. Both siRUNX1 oligoes were used in the RT-qPCR and H3K27ac ChIP-seq experiments. After transfection,
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the samples were incubated for 10 minutes at room temperature before resuspension in KBM and seeding at 50.000 cells per well
(12 well plate). Medium was refreshed each day for the indicated periods till the end of experiments.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are expressed as mean ± standard deviation error of the mean unless otherwise specified. Dataset statistics were analyzed
using theGraphPad Prism software. Differences under p < 0.05were considered statistically significant, NSP value > 0.05, *P value <
0.05, ** P value < 0.01, *** P value < 0.001. Gene expression analysis by RT-qPCR was performed in biological duplicates (n > = 2);
data are shown asmean ± standard deviation, two-way ANOVA. The comparison of gene expression (fold change) was analyzedwith
the unpaired t test. Hypergeometric test was performed with the online tool GeneProf. The comparison of gene expression after
siRNA knockdown was performed with t test. Other statistical methods used in this study were specified in the Figure legends.
DATA AND SOFTWARE AVAILABILITY
To review dataset of control cells, go to GEO database (accession GSE98483) (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE98483). To review our complete dataset in Genome Browser, please go to https://genome.ucsc.edu/cgi-bin/hgTracks?
hgS_doOtherUser=submit&hgS_otherUserName=Jieqiong%20QU&hgS_otherUserSessionName=hg19_p63_RUNX1_Jieqiong
To review dataset of p63 patient cells, go to dbGaP database (accession phs001737.v1.p1) with controlled access (https://www.
ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001737.v1.p1).
All data supporting the findings of the study and in-house codes are available on request.
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